Research programme: cancer therapeutics - Samaritan PharmaceuticalsAlternative Names: SP-4300; SP-C007
Latest Information Update: 03 Apr 2009
At a glance
- Originator Samaritan Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer
Most Recent Events
- 03 Apr 2009 SP-4300 is still in active development
- 20 Aug 2007 Early research in Cancer in USA (unspecified route)